Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-02

AUTHORS

Marc C. Chamberlain, Sandra K. Johnston, Alixis Van Horn, Michael J. Glantz

ABSTRACT

BACKGROUND: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). OBJECTIVE: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. DESIGN: Clinical series of 14 patients with CSF positive lymphomatous meningitis. SETTING: Tertiary-care university medical center. RESULTS: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. CONCLUSIONS: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM. More... »

PAGES

271-277

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-008-9707-1

DOI

http://dx.doi.org/10.1007/s11060-008-9707-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023545868

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18820836


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Murine-Derived", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytarabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Routes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Delivery Systems", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Non-Hodgkin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Meningitis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phospholipids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Neurology, Division of Neuro-Oncology, University of Washington, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, 825 Eastlake Avenue E, MS G4-940, 98109, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chamberlain", 
        "givenName": "Marc C.", 
        "id": "sg:person.01326261166.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seattle Cancer Care Alliance", 
          "id": "https://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "Department of Neurology, Division of Neuro-Oncology, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnston", 
        "givenName": "Sandra K.", 
        "id": "sg:person.01122114252.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122114252.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tufts Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.67033.31", 
          "name": [
            "Department of Neurology, Tufts Medical Center, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Horn", 
        "givenName": "Alixis", 
        "id": "sg:person.0727377047.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727377047.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Utah", 
          "id": "https://www.grid.ac/institutes/grid.223827.e", 
          "name": [
            "Departments of Oncology and Neurosurgery, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Glantz", 
        "givenName": "Michael J.", 
        "id": "sg:person.01044637431.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044637431.67"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/mdl327", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018608852"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archneur.1997.00550190044013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019326341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21828", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023099623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21828", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023099623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(00)00171-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028481559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-005-1096-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029818813", 
          "https://doi.org/10.1007/s00277-005-1096-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-005-1096-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029818813", 
          "https://doi.org/10.1007/s00277-005-1096-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9343(88)90262-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033667260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.7311", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035598225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2004.08.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037122701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-05-2094", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040474917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-06-1636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049256387"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008394827806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01621459.1958.10501452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058299418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.10.3110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074528546"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074559836", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1987.5.10.1655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079675521"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1983.1.9.546", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1081839026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1993.11.3.561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082809600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.4.1561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083246656"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-02", 
    "datePublishedReg": "2009-02-01", 
    "description": "BACKGROUND: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM).\nOBJECTIVE: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM.\nDESIGN: Clinical series of 14 patients with CSF positive lymphomatous meningitis.\nSETTING: Tertiary-care university medical center.\nRESULTS: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients.\nCONCLUSIONS: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-008-9707-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "91"
      }
    ], 
    "name": "Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C", 
    "pagination": "271-277", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "702ddc6ca35d47751fd8d6c563b77cfeb36869e0453e601cbd3727f22594db4e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18820836"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-008-9707-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023545868"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-008-9707-1", 
      "https://app.dimensions.ai/details/publication/pub.1023545868"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000532.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11060-008-9707-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-008-9707-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-008-9707-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-008-9707-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-008-9707-1'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      67 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-008-9707-1 schema:about N10765bf3691645b5ae4d3316050633b1
2 N12fba0571b664db0b57b735657dd6cb4
3 N1b98eef4f287431abadcfaf9d222b2ec
4 N214305d6650b4efdad86ee1c34b021b3
5 N42de71ecc4794a60ae6c7fd6728ff4e9
6 N51a2bb762ff840b6b60abbd6b7760893
7 N58a93ae2809c47b59dea07658d478b5d
8 N6074a7929ce64684b7c8dcdedc5e8c69
9 N60f0186c882649188ef258c4b57f9dc1
10 N6603c28cd9c144a9827a6ca119a678ea
11 N69c8a29ef2824e108e6afa66d1180ca5
12 N77594db2b4374b2a9677aab8f5950ed8
13 N79341e0f54ce44c1be6c722585a5f896
14 N80a63e3553234f2ca86a3f326c5e05c0
15 Na1b0a331214c4bb4a2ad1c91158c0169
16 Nd287c50b000a478c8bcd584bdcbe1c46
17 Nd3fcf57346f64ab0b3278164f9b7165a
18 Nd45bdcc37b814623b5e8527b91b99c9b
19 Nf3ee2742e5e64821ad698a139079cb01
20 Nf9238c8272c94abea333437cdd0e9873
21 anzsrc-for:11
22 anzsrc-for:1109
23 schema:author N291e097e07874ac8a504cbf0dc578b62
24 schema:citation sg:pub.10.1007/s00277-005-1096-3
25 https://app.dimensions.ai/details/publication/pub.1074559836
26 https://doi.org/10.1001/archneur.1997.00550190044013
27 https://doi.org/10.1002/cncr.21828
28 https://doi.org/10.1016/0002-9343(88)90262-8
29 https://doi.org/10.1016/j.ejca.2004.08.012
30 https://doi.org/10.1016/s0959-8049(00)00171-4
31 https://doi.org/10.1023/a:1008394827806
32 https://doi.org/10.1080/01621459.1958.10501452
33 https://doi.org/10.1093/annonc/mdl327
34 https://doi.org/10.1158/1078-0432.ccr-05-2094
35 https://doi.org/10.1182/blood-2002-06-1636
36 https://doi.org/10.1200/jco.1983.1.9.546
37 https://doi.org/10.1200/jco.1987.5.10.1655
38 https://doi.org/10.1200/jco.1993.11.3.561
39 https://doi.org/10.1200/jco.1998.16.4.1561
40 https://doi.org/10.1200/jco.1999.17.10.3110
41 https://doi.org/10.1200/jco.2006.09.7311
42 schema:datePublished 2009-02
43 schema:datePublishedReg 2009-02-01
44 schema:description BACKGROUND: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). OBJECTIVE: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. DESIGN: Clinical series of 14 patients with CSF positive lymphomatous meningitis. SETTING: Tertiary-care university medical center. RESULTS: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. CONCLUSIONS: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.
45 schema:genre research_article
46 schema:inLanguage en
47 schema:isAccessibleForFree false
48 schema:isPartOf N2d74e5d2dbac4458bc535de71028587e
49 N8e13cc4d09654e159a53b808ae35f21c
50 sg:journal.1094205
51 schema:name Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C
52 schema:pagination 271-277
53 schema:productId Na8e50ff273a3484285998ad5ff8c33b4
54 Nb32c1ae0724e4f0cb3d56a1abcb0f343
55 Nbaa9607718aa45898b02ea6325054f9e
56 Ncda5d05bc2d145cd8f500ff4638bbb4c
57 Nde71458d2b91488ebb42016cd6f6a6e4
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023545868
59 https://doi.org/10.1007/s11060-008-9707-1
60 schema:sdDatePublished 2019-04-10T19:12
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N41811f9bec1340f390b9892f3b8990b6
63 schema:url http://link.springer.com/10.1007%2Fs11060-008-9707-1
64 sgo:license sg:explorer/license/
65 sgo:sdDataset articles
66 rdf:type schema:ScholarlyArticle
67 N07bf63f63293468786f5887cd6fe916b schema:name Department of Neurology, Division of Neuro-Oncology, University of Washington, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, 825 Eastlake Avenue E, MS G4-940, 98109, Seattle, WA, USA
68 rdf:type schema:Organization
69 N10765bf3691645b5ae4d3316050633b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Combined Modality Therapy
71 rdf:type schema:DefinedTerm
72 N12fba0571b664db0b57b735657dd6cb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Antibodies, Monoclonal, Murine-Derived
74 rdf:type schema:DefinedTerm
75 N1b98eef4f287431abadcfaf9d222b2ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Humans
77 rdf:type schema:DefinedTerm
78 N1fd44617e07841b78492a381305ba4fb rdf:first sg:person.01122114252.85
79 rdf:rest N94ab1dd345e747478c3679c73ba101a8
80 N214305d6650b4efdad86ee1c34b021b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Antineoplastic Agents
82 rdf:type schema:DefinedTerm
83 N291e097e07874ac8a504cbf0dc578b62 rdf:first sg:person.01326261166.36
84 rdf:rest N1fd44617e07841b78492a381305ba4fb
85 N2d74e5d2dbac4458bc535de71028587e schema:volumeNumber 91
86 rdf:type schema:PublicationVolume
87 N41811f9bec1340f390b9892f3b8990b6 schema:name Springer Nature - SN SciGraph project
88 rdf:type schema:Organization
89 N42de71ecc4794a60ae6c7fd6728ff4e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Drug Administration Routes
91 rdf:type schema:DefinedTerm
92 N51a2bb762ff840b6b60abbd6b7760893 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Drug Delivery Systems
94 rdf:type schema:DefinedTerm
95 N58a93ae2809c47b59dea07658d478b5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Male
97 rdf:type schema:DefinedTerm
98 N6074a7929ce64684b7c8dcdedc5e8c69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Neoplasm Recurrence, Local
100 rdf:type schema:DefinedTerm
101 N60f0186c882649188ef258c4b57f9dc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Female
103 rdf:type schema:DefinedTerm
104 N6603c28cd9c144a9827a6ca119a678ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Survival Analysis
106 rdf:type schema:DefinedTerm
107 N69c8a29ef2824e108e6afa66d1180ca5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Meningitis
109 rdf:type schema:DefinedTerm
110 N77594db2b4374b2a9677aab8f5950ed8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Adult
112 rdf:type schema:DefinedTerm
113 N79341e0f54ce44c1be6c722585a5f896 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Cytarabine
115 rdf:type schema:DefinedTerm
116 N80a63e3553234f2ca86a3f326c5e05c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Aged
118 rdf:type schema:DefinedTerm
119 N8e13cc4d09654e159a53b808ae35f21c schema:issueNumber 3
120 rdf:type schema:PublicationIssue
121 N94ab1dd345e747478c3679c73ba101a8 rdf:first sg:person.0727377047.36
122 rdf:rest Nbf53ac66e69e4b05b13fed0bfcccc69b
123 Na1b0a331214c4bb4a2ad1c91158c0169 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Antibodies, Monoclonal
125 rdf:type schema:DefinedTerm
126 Na8e50ff273a3484285998ad5ff8c33b4 schema:name dimensions_id
127 schema:value pub.1023545868
128 rdf:type schema:PropertyValue
129 Nb32c1ae0724e4f0cb3d56a1abcb0f343 schema:name doi
130 schema:value 10.1007/s11060-008-9707-1
131 rdf:type schema:PropertyValue
132 Nbaa9607718aa45898b02ea6325054f9e schema:name nlm_unique_id
133 schema:value 8309335
134 rdf:type schema:PropertyValue
135 Nbf53ac66e69e4b05b13fed0bfcccc69b rdf:first sg:person.01044637431.67
136 rdf:rest rdf:nil
137 Ncda5d05bc2d145cd8f500ff4638bbb4c schema:name readcube_id
138 schema:value 702ddc6ca35d47751fd8d6c563b77cfeb36869e0453e601cbd3727f22594db4e
139 rdf:type schema:PropertyValue
140 Nd287c50b000a478c8bcd584bdcbe1c46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Middle Aged
142 rdf:type schema:DefinedTerm
143 Nd3fcf57346f64ab0b3278164f9b7165a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Lymphoma, Non-Hodgkin
145 rdf:type schema:DefinedTerm
146 Nd45bdcc37b814623b5e8527b91b99c9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Phospholipids
148 rdf:type schema:DefinedTerm
149 Nde71458d2b91488ebb42016cd6f6a6e4 schema:name pubmed_id
150 schema:value 18820836
151 rdf:type schema:PropertyValue
152 Nf3ee2742e5e64821ad698a139079cb01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Rituximab
154 rdf:type schema:DefinedTerm
155 Nf9238c8272c94abea333437cdd0e9873 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Follow-Up Studies
157 rdf:type schema:DefinedTerm
158 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
159 schema:name Medical and Health Sciences
160 rdf:type schema:DefinedTerm
161 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
162 schema:name Neurosciences
163 rdf:type schema:DefinedTerm
164 sg:journal.1094205 schema:issn 0167-594X
165 1573-7373
166 schema:name Journal of Neuro-Oncology
167 rdf:type schema:Periodical
168 sg:person.01044637431.67 schema:affiliation https://www.grid.ac/institutes/grid.223827.e
169 schema:familyName Glantz
170 schema:givenName Michael J.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044637431.67
172 rdf:type schema:Person
173 sg:person.01122114252.85 schema:affiliation https://www.grid.ac/institutes/grid.430269.a
174 schema:familyName Johnston
175 schema:givenName Sandra K.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122114252.85
177 rdf:type schema:Person
178 sg:person.01326261166.36 schema:affiliation N07bf63f63293468786f5887cd6fe916b
179 schema:familyName Chamberlain
180 schema:givenName Marc C.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36
182 rdf:type schema:Person
183 sg:person.0727377047.36 schema:affiliation https://www.grid.ac/institutes/grid.67033.31
184 schema:familyName Van Horn
185 schema:givenName Alixis
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727377047.36
187 rdf:type schema:Person
188 sg:pub.10.1007/s00277-005-1096-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029818813
189 https://doi.org/10.1007/s00277-005-1096-3
190 rdf:type schema:CreativeWork
191 https://app.dimensions.ai/details/publication/pub.1074559836 schema:CreativeWork
192 https://doi.org/10.1001/archneur.1997.00550190044013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019326341
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1002/cncr.21828 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023099623
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1016/0002-9343(88)90262-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033667260
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/j.ejca.2004.08.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037122701
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/s0959-8049(00)00171-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028481559
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1023/a:1008394827806 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303712
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1080/01621459.1958.10501452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058299418
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1093/annonc/mdl327 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018608852
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1158/1078-0432.ccr-05-2094 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040474917
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1182/blood-2002-06-1636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049256387
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1200/jco.1983.1.9.546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081839026
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1200/jco.1987.5.10.1655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079675521
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1200/jco.1993.11.3.561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082809600
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1200/jco.1998.16.4.1561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083246656
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1200/jco.1999.17.10.3110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074528546
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1200/jco.2006.09.7311 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035598225
223 rdf:type schema:CreativeWork
224 https://www.grid.ac/institutes/grid.223827.e schema:alternateName University of Utah
225 schema:name Departments of Oncology and Neurosurgery, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, USA
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.430269.a schema:alternateName Seattle Cancer Care Alliance
228 schema:name Department of Neurology, Division of Neuro-Oncology, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.67033.31 schema:alternateName Tufts Medical Center
231 schema:name Department of Neurology, Tufts Medical Center, Boston, MA, USA
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...